Trinity Biotech plc (TRIB), a leading developer of diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market, has seen its stock price touch a 52-week low, ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced new ...

The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than ...

Trinity announced results from its pre-pivotal clinical trial for continuous glucose monitoring system. The trial results indicated a 25% to 30% improvement in accuracy over earlier CGM sensors.

DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced ...